GABINET LEKARSKI MALGORZATA SARYUSZ-WOLSKA

The site focuses on type 2 diabetes and type 1 diabetes within the broader field of nutritional and metabolic diseases. Trials aim to evaluate new weekly insulin‑semaglutide combinations and weekly insulin formulations to improve glycaemic control and simplify treatment.

• Weekly insulin‑semaglutide combo for better HbA1c
• Once‑weekly insulin icodec versus daily insulin glargine
• Combination therapy with insulin aspart
• Non‑inferiority and superiority assessments

These studies seek to reduce injection frequency, enhance blood‑sugar stability, and offer patients more convenient therapeutic options.

Research also targets chronic kidney disease in people with overweight or obesity and type 2 diabetes, falling under the nutritional and metabolic diseases therapeutic area. The goal is to test novel agents that may slow kidney‑disease progression and promote weight loss.

• CagriSema impact on kidney disease markers
• Comparative study of CagriSema versus cagrilintide and placebo
• Weight‑loss efficacy of NNC0487‑0111 versus semaglutide
• Surrogate endpoints for renal function

By addressing both metabolic control and renal outcomes, the trials aim to improve long‑term health for patients struggling with obesity‑related kidney risk.